022 82 44 44

Brain tumors account for 85%–90% of all primary tumors of the central nervous system (CNS). Diagnosis of glial malignancies of the brain is based on histopathological examination of tumor tissue obtained through invasive sample collection (biopsy or surgical excision).
The risks associated with biopsies are well known: pain and discomfort, intracranial hemorrhage, cerebral edema, infection, morbidity (25-30%), and mortality
Approximately 70% of patients with radiological intracranial mass lesions undergoing biopsy, are found to be non-malignant, indicating a high proportion of people undergoing invasive procedures that are retrospectively deemed unnecessary.
Thus, non-invasive detection of biomarkers of malignancy has significant advantages – reduction of risks, optimization of resources, cost savings, and avoidance of delays in diagnosis and treatment time, especially in inoperable cases where tissue sampling is not feasible.

Features

Trublood CNS has a very high accuracy in detecting primary glial malignancies of various grades of malignancy (II-IV) and their subtypes: gliomas, astrocytomas, oligodendrogliomas, oligoastrocytomas and glioblastomas regardless of gender and age.

Features

Trublood CNS has a very high accuracy in detecting primary glial malignancies of various grades of malignancy (II-IV) and their subtypes: gliomas, astrocytomas, oligodendrogliomas, oligoastrocytomas and glioblastomas regardless of gender and age.

High clinical sensitivity of the test indicates a very low risk of "missing" any primary glial malignant tumor
High clinical specificity of the test indicates an almost complete absence of the risk of false-positive results in individuals without a primary glial malignant tumor

Indications

Patients with suspected glial malignant tumors based on clinical-laboratory and/or imaging (MRI) data, to whom invasive tissue sampling is recommended as part of standard diagnostic evaluation
Patients requiring diagnostic support for inoperable and/or non-biopsied intracranial mass lesions
Patients with inconclusive biopsy results or results that do not align with clinical observations
Patients suspected of recurrence who have previously been diagnosed and treated for a glial malignant tumor

Trublood CNS is not proposed:

To replace standard tissue biopsy-based diagnostics in patients where it is recommended, necessary, and feasible
To detect uncommon subtypes (lymphomas, gliosarcomas)
To determine the subtype or grade of malignancy

Diagnostic Characteristics

Clinical validation studies have demonstrated an overall (cumulative) sensitivity of >99% and 100% specificity for detecting circulating malignant glial cells

Decided to take the test!

Book your first consultation with a doctor

The doctor will inform you about the upcoming testing, answer any questions you may have, and then ask you to sign an informed consent form for the test. Then, the doctor will complete a special form (application) according to the requirements of Trublood

Book a consultation

Where can I get tested?

Chisinau

21 N. Теstemițanu, street
Monday – Tuesday, 07:30 - 14:30 I Wednesday, 07:30 - 09:00

Laboratory Report

The test results provided in the laboratory report are intended for professional use only by qualified specialists, considering the capabilities/limitations/characteristics of the test, the patient's current health status, clinical history, and diagnostic data, and, if necessary, should be confirmed/excluded by standard medical procedures.

VIEW SAMPLE REPORTS IN ENGLISH

Not detected

Detected